425 related articles for article (PubMed ID: 20221637)
1. Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells.
Röhrl C; Kaindl U; Koneczny I; Hudec X; Baron DM; König JS; Marian B
J Cancer Res Clin Oncol; 2011 Jan; 137(1):29-39. PubMed ID: 20221637
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
4. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
Hollingshead HE; Killins RL; Borland MG; Girroir EE; Billin AN; Willson TM; Sharma AK; Amin S; Gonzalez FJ; Peters JM
Carcinogenesis; 2007 Dec; 28(12):2641-9. PubMed ID: 17693664
[TBL] [Abstract][Full Text] [Related]
6. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
7. The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism.
Roche E; Lascombe I; Bittard H; Mougin C; Fauconnet S
Cell Signal; 2014 Feb; 26(2):433-43. PubMed ID: 24172859
[TBL] [Abstract][Full Text] [Related]
8. Stable over-expression of PPARβ/δ and PPARγ to examine receptor signaling in human HaCaT keratinocytes.
Borland MG; Khozoie C; Albrecht PP; Zhu B; Lee C; Lahoti TS; Gonzalez FJ; Peters JM
Cell Signal; 2011 Dec; 23(12):2039-50. PubMed ID: 21843636
[TBL] [Abstract][Full Text] [Related]
9. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis.
Piqueras L; Reynolds AR; Hodivala-Dilke KM; Alfranca A; Redondo JM; Hatae T; Tanabe T; Warner TD; Bishop-Bailey D
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):63-9. PubMed ID: 17068288
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor β/δ and γ agonists differentially affect prostaglandin E2 and cytokine synthesis and nutrient transporter expression in porcine trophoblast cells during implantation.
Blitek A; Szymanska M
Theriogenology; 2020 Aug; 152():36-46. PubMed ID: 32361305
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Aleshin S; Strokin M; Sergeeva M; Reiser G
Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of peroxisome proliferator-activated receptor isoforms alpha, beta/delta, and gamma mediate distinct facets of hypertrophic transformation of adult cardiac myocytes.
Pellieux C; Montessuit C; Papageorgiou I; Lerch R
Pflugers Arch; 2007 Dec; 455(3):443-54. PubMed ID: 17643263
[TBL] [Abstract][Full Text] [Related]
13. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha--brief report.
Ali FY; Hall MG; Desvergne B; Warner TD; Mitchell JA
Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1871-3. PubMed ID: 19696401
[TBL] [Abstract][Full Text] [Related]
14. Role of peroxisome proliferator-activated receptor beta/delta in chicken adipogenesis.
Sato K; Yonemura T; Ishii H; Toyomizu M; Kamada T; Akiba Y
Comp Biochem Physiol A Mol Integr Physiol; 2009 Nov; 154(3):370-5. PubMed ID: 19619666
[TBL] [Abstract][Full Text] [Related]
15. PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium.
Scoditti E; Massaro M; Carluccio MA; Distante A; Storelli C; De Caterina R
Cardiovasc Res; 2010 May; 86(2):302-10. PubMed ID: 20032081
[TBL] [Abstract][Full Text] [Related]
16. Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha.
Han S; Ritzenthaler JD; Sun X; Zheng Y; Roman J
Am J Respir Cell Mol Biol; 2009 Mar; 40(3):325-31. PubMed ID: 18776129
[TBL] [Abstract][Full Text] [Related]
17. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate.
Takacs ML; Abbott BD
Toxicol Sci; 2007 Jan; 95(1):108-17. PubMed ID: 17047030
[TBL] [Abstract][Full Text] [Related]
18. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta.
Han S; Ritzenthaler JD; Wingerd B; Roman J
J Biol Chem; 2005 Sep; 280(39):33240-9. PubMed ID: 16061473
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
20. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.
Palkar PS; Borland MG; Naruhn S; Ferry CH; Lee C; Sk UH; Sharma AK; Amin S; Murray IA; Anderson CR; Perdew GH; Gonzalez FJ; Müller R; Peters JM
Mol Pharmacol; 2010 Sep; 78(3):419-30. PubMed ID: 20516370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
